Larry Norton

Oct 17, 2024 | nature.com | Nicholas Mai |Pedram Razavi |Anton Safonov |Chau Dang |Larry Norton |Mark E. Robson | +1 more

AbstractAfter disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.

Sep 18, 2023 | newsday.com | Larry Norton

All of us involved in cancer research and patient care are gratified to see the growing public awareness of the remarkable advances underway in the fight against cancer. Cure rates for newly diagnosed cases are improving for many cancers, with an expanding emphasis on minimizing the side effects of the treatments needed to accomplish these cures.

Feb 21, 2023 | annalsofglobalhealth.org | Ghassan Abou Alfa |Larry Norton

As it is increasingly recognized that preventive approaches could have a substantial impact on cancer mortality worldwide, hereditary and environmental risk factors provide an important target for intervention. It is estimated that over half of cancer deaths could be prevented by addressing smoking and known environmental, dietary, infectious, and other causes of cancer [1].